CR9146A - Sal potasica de un inhibidor de la integrasa de vih - Google Patents

Sal potasica de un inhibidor de la integrasa de vih

Info

Publication number
CR9146A
CR9146A CR9146A CR9146A CR9146A CR 9146 A CR9146 A CR 9146A CR 9146 A CR9146 A CR 9146A CR 9146 A CR9146 A CR 9146A CR 9146 A CR9146 A CR 9146A
Authority
CR
Costa Rica
Prior art keywords
inhibitor
hiv
integras
potassic salt
compound
Prior art date
Application number
CR9146A
Other languages
English (en)
Inventor
G Morrison Henry
Jones Philip
Summa Vicenzo
M Belyk Kevin
Original Assignee
Istituto Di Recerche Di Biolog A Molecolare P Angeletti Spa
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36171569&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CR9146(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Istituto Di Recerche Di Biolog A Molecolare P Angeletti Spa, Merck Sharp & Dohme filed Critical Istituto Di Recerche Di Biolog A Molecolare P Angeletti Spa
Publication of CR9146A publication Critical patent/CR9146A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
    • C07D239/545—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/557—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms, e.g. orotic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D313/00—Heterocyclic compounds containing rings of more than six members having one oxygen atom as the only ring hetero atom
    • C07D313/02—Seven-membered rings
    • C07D313/06—Seven-membered rings condensed with carbocyclic rings or ring systems
    • C07D313/10—Seven-membered rings condensed with carbocyclic rings or ring systems condensed with two six-membered rings
    • C07D313/12—[b,e]-condensed

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se describen sales potasicas del Compuesto A y procedimientos para su preparacion, en las que Compuesto A es de la formula que se muestra. El compuesto A es un inhibidor de la integrasa de VIH, para retrasar el inicio del SIDA, y para el tratamiento o la profilaxis del SIDA.
CR9146A 2004-12-03 2007-05-23 Sal potasica de un inhibidor de la integrasa de vih CR9146A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US63313204P 2004-12-03 2004-12-03

Publications (1)

Publication Number Publication Date
CR9146A true CR9146A (es) 2007-10-04

Family

ID=36171569

Family Applications (1)

Application Number Title Priority Date Filing Date
CR9146A CR9146A (es) 2004-12-03 2007-05-23 Sal potasica de un inhibidor de la integrasa de vih

Country Status (35)

Country Link
US (2) US7754731B2 (es)
EP (2) EP1819700B1 (es)
JP (1) JP4705956B2 (es)
KR (2) KR20130122031A (es)
CN (1) CN101068793B (es)
AR (2) AR052034A1 (es)
AT (2) ATE518844T1 (es)
AU (1) AU2005311671B8 (es)
BR (1) BRPI0518760A8 (es)
CA (1) CA2588398C (es)
CR (1) CR9146A (es)
CY (1) CY1112859T1 (es)
DK (1) DK1819700T3 (es)
EA (1) EA012418B1 (es)
ES (2) ES2370136T3 (es)
GE (1) GEP20105086B (es)
HR (1) HRP20120066T1 (es)
IL (1) IL183614A (es)
MA (1) MA29120B1 (es)
ME (1) ME01985B (es)
MX (1) MX2007006639A (es)
MY (1) MY144320A (es)
NI (1) NI200700138A (es)
NO (1) NO338784B1 (es)
NZ (1) NZ555376A (es)
PE (1) PE20061148A1 (es)
PL (1) PL1819700T3 (es)
PT (1) PT1819700E (es)
RS (1) RS52197B (es)
SI (1) SI1819700T1 (es)
TN (1) TNSN07215A1 (es)
TW (1) TWI344463B (es)
UA (1) UA87884C2 (es)
WO (2) WO2006060712A2 (es)
ZA (1) ZA200704130B (es)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL1725528T3 (pl) 2004-03-11 2013-12-31 4Sc Ag Sulfonylopirole jako inhibitory HDAC
US20070259894A1 (en) * 2004-12-03 2007-11-08 Kelem Kassahun Use of Atazanavir for Improving the Pharmacokinetics of Drugs Metabolized by Ugt1a1
EP2586444B1 (en) * 2004-12-03 2019-09-25 Merck Sharp & Dohme Corp. Pharmaceutical formulation of carboxamide HIV integrase inhibitors containing a release rate control composition
ES2727577T5 (en) * 2004-12-03 2025-04-02 Merck Sharp & Dohme Llc Pharmaceutical composition containing an anti-nucleating agent
TW200810789A (en) * 2006-03-14 2008-03-01 Merck & Co Inc Processes and apparatuses for the production of crystalline organic microparticle compositions by micro-milling and crystallization on micro-seed and their use
WO2008010953A2 (en) 2006-07-19 2008-01-24 University Of Georgia Research Foundation, Inc. Pyridinone diketo acids: inhibitors of hiv replication in combination therapy
WO2009009531A2 (en) * 2007-07-09 2009-01-15 Concert Pharmaceuticals Inc. Pyrimidinecarboxamide derivatives for the treatment of hiv infections
CN101918372B (zh) * 2008-01-08 2014-03-26 默沙东公司 用于制备n-取代的羟基嘧啶酮羧酰胺类化合物的方法
ES2549387T3 (es) * 2009-06-02 2015-10-27 Hetero Research Foundation Procedimiento de preparación de raltegravir potásico amorfo
WO2011024192A2 (en) 2009-07-27 2011-03-03 Matrix Laboratories Ltd Novel polymorphs of raltegravir
EP3970702A1 (en) 2009-10-26 2022-03-23 Merck Sharp & Dohme Corp. Solid pharmaceutical compositions containing an integrase inhibitor
DE102009056636A1 (de) 2009-12-02 2011-06-09 Ratiopharm Gmbh Raltegravir-Polymorphe
AU2010328325B2 (en) 2009-12-07 2015-02-05 University Of Georgia Research Foundation, Inc. Pyridinone hydroxycyclopentyl carboxamides: HIV integrase inhibitors with therapeutic applications
ES2362598B1 (es) * 2009-12-17 2012-06-13 Consejo Superior De Investigaciones Científicas (Csic) Uso del raltegravir y derivados para la elaboración de medicamentos destinados al tratamiento de infecciones por herpesvirus.
EP2545048B1 (en) * 2010-04-01 2014-10-08 Teva Pharmaceutical Industries Ltd. Raltegravir salts and crystalline forms thereof
US8987272B2 (en) * 2010-04-01 2015-03-24 Critical Outcome Technologies Inc. Compounds and method for treatment of HIV
WO2011148381A1 (en) * 2010-05-25 2011-12-01 Hetero Research Foundation Salts of raltegravir
US9107922B2 (en) 2010-07-16 2015-08-18 Concert Pharmaceuticals, Inc. Pyrimidinecarboxamide derivatives
CN101914067B (zh) * 2010-08-26 2012-07-11 陈岱岭 N-甲基嘧啶酮的合成方法
JO3209B1 (ar) * 2010-11-05 2018-03-08 H Lundbeck As طريقة لتصنيع نالتريكسون
WO2012103105A1 (en) 2011-01-24 2012-08-02 Assia Chemical Industries Ltd. Processes for preparing raltegravir and intermediates in the processes
WO2012106534A2 (en) * 2011-02-02 2012-08-09 The Regents Of The University Of California Hiv integrase inhibitors
US9163009B2 (en) 2011-04-06 2015-10-20 Lupin Limited Salts of raltegravir
EP2699094A4 (en) * 2011-04-22 2014-12-17 Merck Sharp & Dohme TASTE-MASKED FORMULATIONS BY RALTEGRAVIR
US9968607B2 (en) 2011-04-25 2018-05-15 Hetero Research Foundation Pharmaceutical compositions of raltegravir, methods of preparation and methods of use therof
EP2522665A1 (en) 2011-05-03 2012-11-14 Sandoz Ag Crystalline sodium salt of an HIV integrase inhibitor
ES2450944T3 (es) 2011-06-01 2014-03-25 Ratiopharm Gmbh Composición y comprimido que comprenden raltegravir
EP2755968A1 (de) 2011-09-16 2014-07-23 Hexal AG Neue polymorphe form von raltegravir-kalium
CN103130788B (zh) * 2011-11-24 2015-09-02 南开大学 嘧啶酰胺类化合物及其制备方法、抗hiv活性和抗tmv活性
CN103130787B (zh) * 2011-11-24 2015-06-10 南开大学 嘧啶酮酰胺类化合物及其制备方法、抗hiv活性和抗tmv活性
WO2013098854A2 (en) * 2011-12-26 2013-07-04 Emcure Pharmaceuticals Limited Synthesis of raltegravir
MX2014009015A (es) 2012-01-25 2014-12-08 Lupin Ltd Premezcla de potasio de raltegravir amorfo estable y proceso para la preparacion de la misma.
WO2014064711A2 (en) * 2012-10-22 2014-05-01 Hetero Research Foundation Methods of administering raltegravir and raltegravir compositions
EP2818470A1 (en) 2013-06-27 2014-12-31 Basf Se Cocrystals of raltegravir potassium
WO2015009927A1 (en) * 2013-07-17 2015-01-22 Ratiopharm Gmbh Dolutegravir salts
US20170253585A1 (en) 2014-02-03 2017-09-07 Mylan Laboratories Ltd. Processes for the preparation of intermediates of raltegravir
EP3119773A1 (en) 2014-03-21 2017-01-25 Mylan Laboratories Ltd. A premix of crystalline raltegravir potassium salt and a process for the preparation thereof
US10257840B2 (en) 2014-10-22 2019-04-09 Telefonaktiebolaget Lm Ericsson (Publ) Operation of wireless local area network in the presence of periodic interference
WO2016075605A1 (en) 2014-11-10 2016-05-19 Aurobindo Pharma Ltd An improved process for the preparation of raltegravir
EP3472134B1 (en) * 2016-06-21 2021-10-20 Pharmathen S.A. Process for preparing compounds useful as intermediates for the preparation of raltegravir
AU2017329049A1 (en) 2016-09-15 2019-04-04 Lupin Limited Process for the preparation of pure and stable crystalline Raltegravir potassium Form 3
CN108610338A (zh) * 2016-12-12 2018-10-02 天津国际生物医药联合研究院 一种嘧啶酮酰胺类化合物的制备方法
US11246869B2 (en) 2017-11-14 2022-02-15 Cambrex Profarmaco Milano S.R.L. Process for the preparation of Raltegravir
EP3801532B1 (en) * 2018-06-06 2025-11-05 Merck Sharp & Dohme LLC Formulations of raltegravir
GB201907305D0 (en) * 2019-05-23 2019-07-10 Douglas Pharmaceuticals Ltd Treatment of conditions
US12465565B2 (en) 2020-01-23 2025-11-11 Lupin Limited Pharmaceutical compositions of raltegravir

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH624391A5 (es) * 1976-12-14 1981-07-31 Ciba Geigy Ag
US5413999A (en) 1991-11-08 1995-05-09 Merck & Co., Inc. HIV protease inhibitors useful for the treatment of AIDS
US5717097A (en) 1991-11-08 1998-02-10 Merck & Co., Inc. HIV protease inhibitors useful for the treatment of AIDS
IL121789A (en) * 1996-10-03 2001-06-14 Rohm & Haas A medicinal product for inhibiting mammalian cell tumors
ID29027A (id) 1998-12-25 2001-07-26 Shionogi & Co Turunan-turunan heteroaromatik yang mempunyai aktivitas penghambatan terhadap integrase hiv
IT1318424B1 (it) 2000-03-24 2003-08-25 Unihart Corp Composti con attivita' anti-hiv.
WO2002030931A2 (en) 2000-10-12 2002-04-18 Merck & Co., Inc. Aza- and polyaza-naphthalenyl carboxamides useful as hiv integrase inhibitors
GB0028483D0 (en) 2000-11-22 2001-01-10 Hoffmann La Roche Hydroxyethylamine HIV protease inhibitors
HU230248B1 (hu) * 2001-10-26 2015-11-30 Msd Italia S.R.L. N-szubsztituált hidroxipirimidinon-karboxamid HIV-integráz inhibitorok
BRPI0215050B8 (pt) 2001-12-21 2021-05-25 Anormed Inc compostos heterocíclicos de ligação a receptor de quimiocina, seus usos no tratamento de condições relacionadas aos receptores de quimiocinas, doenças inflamatórias, alérgicas e autoimunes, bem como composições farmacêuticas que os compreendem
US7354932B2 (en) 2001-12-21 2008-04-08 Anormed, Inc. Chemokine receptor binding heterocyclic compounds with enhanced efficacy
US7176220B2 (en) 2002-11-20 2007-02-13 Japan Tobacco Inc. 4-oxoquinoline compound and use thereof as pharmaceutical agent
MXPA05007010A (es) 2002-12-27 2005-08-18 Angeletti P Ist Richerche Bio Tetrahidro-4h-pirido[1,2-a]pirimidinas y compuestos relacionados utiles como inhibidores de la integrasa del virus de inmunodeficiencia humana.
TW200423930A (en) 2003-02-18 2004-11-16 Hoffmann La Roche Non-nucleoside reverse transcriptase inhibitors
EP2586444B1 (en) 2004-12-03 2019-09-25 Merck Sharp & Dohme Corp. Pharmaceutical formulation of carboxamide HIV integrase inhibitors containing a release rate control composition
ES2727577T5 (en) 2004-12-03 2025-04-02 Merck Sharp & Dohme Llc Pharmaceutical composition containing an anti-nucleating agent
US20070259894A1 (en) 2004-12-03 2007-11-08 Kelem Kassahun Use of Atazanavir for Improving the Pharmacokinetics of Drugs Metabolized by Ugt1a1

Also Published As

Publication number Publication date
EA012418B1 (ru) 2009-10-30
NO338784B1 (no) 2016-10-17
AU2005311671B8 (en) 2011-02-10
NI200700138A (es) 2008-05-13
PT1819700E (pt) 2012-02-01
WO2006060730A3 (en) 2006-08-17
TWI344463B (en) 2011-07-01
MA29120B1 (fr) 2007-12-03
HRP20120066T1 (hr) 2012-03-31
ATE534645T1 (de) 2011-12-15
EP1819700B1 (en) 2011-11-23
GEP20105086B (en) 2010-10-11
US20100249410A1 (en) 2010-09-30
WO2006060712A2 (en) 2006-06-08
IL183614A0 (en) 2007-09-20
KR20130122031A (ko) 2013-11-06
EP1819683B1 (en) 2011-08-03
AU2005311671A1 (en) 2006-06-08
NO20073404L (no) 2007-07-02
ATE518844T1 (de) 2011-08-15
AR101429A2 (es) 2016-12-21
PL1819700T3 (pl) 2012-04-30
MY144320A (en) 2011-08-29
PE20061148A1 (es) 2006-11-09
SI1819700T1 (sl) 2012-07-31
EP1819700A2 (en) 2007-08-22
AR052034A1 (es) 2007-02-28
US8357798B2 (en) 2013-01-22
HK1115011A1 (en) 2008-11-14
MX2007006639A (es) 2007-06-19
IL183614A (en) 2012-03-29
CN101068793B (zh) 2011-05-25
KR20070089990A (ko) 2007-09-04
US20060122205A1 (en) 2006-06-08
CA2588398A1 (en) 2006-06-08
TW200631944A (en) 2006-09-16
CN101068793A (zh) 2007-11-07
EP1819683A2 (en) 2007-08-22
JP2008521933A (ja) 2008-06-26
WO2006060730A2 (en) 2006-06-08
BRPI0518760A8 (pt) 2017-12-12
ZA200704130B (en) 2008-08-27
CA2588398C (en) 2011-07-12
EA200701204A1 (ru) 2007-12-28
JP4705956B2 (ja) 2011-06-22
BRPI0518760A2 (pt) 2008-12-09
US7754731B2 (en) 2010-07-13
ME01985B (me) 2012-10-31
CY1112859T1 (el) 2016-04-13
NZ555376A (en) 2009-11-27
ES2375788T3 (es) 2012-03-06
ES2370136T3 (es) 2011-12-13
KR101350420B1 (ko) 2014-02-17
RS52197B (sr) 2012-10-31
TNSN07215A1 (en) 2008-11-21
DK1819700T3 (da) 2012-03-19
WO2006060712A9 (en) 2006-07-27
AU2005311671B2 (en) 2011-01-27
WO2006060712A3 (en) 2006-09-21
UA87884C2 (uk) 2009-08-25

Similar Documents

Publication Publication Date Title
CR9146A (es) Sal potasica de un inhibidor de la integrasa de vih
AR121611A2 (es) Inhibidores de glucosilceramida sintasa
MD20160117A2 (ro) Derivaţi nucleozidici 4'-substituiţi în calitate de inhibitori ai transcriptazei inverse a HIV
CO6660497A2 (es) Derivados del ácido nft-2-ilacético para tratar el sida
ECSP066826A (es) Inhibidores de integrasa de vih
DOP2020000083A (es) Compuesto de pirimidina como inhibidor de las janocinasas
CR20120503A (es) Inhibidores no nucleosídicos de la transcriptasa inversa
UY38559A (es) Inhibidores de la replicación del virus de la inmunodeficiencia humana
BR112018011788A2 (pt) formas sólidas de éster etílico de ácido (2r,4s)-5-(bifenil-4-il)-4-[(3-carboxipropionil)amino]-2-metil-pentanoico, seus sais e um método de preparação
DOP2018000183A (es) Compuesto útil para el tratamiento y la profilaxis de vih y sida y sus usos
CR20110184A (es) Inhibidores de la integrasa del vih
CO2018007008A2 (es) "procesos mejorados para la preparación de osimertinib (azd9291) o una sal del mismo y "azd9291 anilina" o una sal del mismo"
CL2019003107A1 (es) Compuestos heterocíclicos bicíclicos sustituidos utilizados como inhibidores de nadph oxidasa.
CO2021009309A2 (es) Formas de sal y cristalinas de un compuesto orgánico y composiciones farmacéuticas del mismo
CL2011001829A1 (es) 3'-n-desmetil-4''-o-(2-dietilaminoetanoil)-6-o-metil-9a-aza-9a-homoeritromicina a, sus sales y formas cristalinas 1, 2 y 3; proceso de preparacion; uso para tratar enfermedades inflamatorias; composicion farmaceutica; y composicion que ademas comprende otro compuesto activo.
UY27809A1 (es) Inhibidores de la transcriptasa inversa no nucleosidos
UY28248A1 (es) Compuestos quinicos
AR077692A1 (es) Sales de 2-((r)-(3-clorofenil) ((r)-1-((s) -2-(metilamino)-3-((r)-tetrahidro-2h-piran-3-il) propilcarbamoil) piperidin -3-il) metoxi) etilcarbamato de metilo
CL2008001537A1 (es) Compuestos heterociclo derivados de 1h-pirimidin-2,4-diona, dihidro-pirimidin-2,4-diona e imidazol-2,4-diona, inhibidores no nucleosidos de la transcriptasa inversa (nnrti) del vih-1; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar enfermedades mediadas por vih, sida o arc.
ECSP22046595A (es) Procesos e intermediario para la preparaci?n de oxetan-2-ilmetanamina
ATE380188T1 (de) Substituierte chinolone
AR053345A1 (es) Compuesto de 1,2,4 triazolo-5-ona como inhibidores de la transcriptasa inversa
DOP2005000244A (es) Sal potasica de un inhibidor de la integrasa del vih
MX2022011475A (es) Azd1656 para el uso en el tratamiento de neumonitis y/o la miocarditis causadas por un coronavirus.
ATE420089T1 (de) Substituierte azachinazoline mit antiviraler wirkung

Legal Events

Date Code Title Description
FC Refusal